Christopher Martell

Christopher Martell is a declared insider of Candel Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). The record holds 7 filings, for trades running from 29 July 2021 to 25 June 2025.

Every open-market trade on record is a purchase: 5 purchases worth €938k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant.

Half of the purchases are above €44k and half below. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 26 June 2025 came the latest disclosure, a share grant for €445k in Candel Therapeutics, Inc. The latest purchase dates back some time: it was published 1,344 days ago, on 17 February 2023. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.